News

The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.

The latest IOLs offer an improvement in stray light performance and enhanced contrast.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

In a presentation at the Asia-Pacific Academy of Ophthalmology Congress in Kuala Lumpur, Malaysia, Kyoko Ohno-Matsui, MD, PhD, noted that changes of scleral curvature and staphyloma edge development may occur in synchronicity.

According to Regeneron, the BLA is supported by two pivotal trials demonstrating non-inferior vision gains to aflibercept injection, with a majority of patients maintaining extended dosing regimens through 48 weeks.

Global Pharma agrees to recall Delsam Pharma’s over-the-counter Artificial Eye Ointment due to potential bacterial contamination.

Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Ophthalmologists should be aware of a patient’s prior history

Multiple attendees of this year's EnVision Summit share insights into what makes the EnVision Summit an enjoyable experience and a great place to learn.

The considerations for biosimilars in clinical practice are interesting and remain to be determined, according to George A. Williams, MD.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

Ophthalmologists see new therapy as having a major impact on how geographic atrophy is treated.

Multiple attendees of this year's EnVision Summit share insights into their presentations.

Sessions offer training in ophthalmic translational research, problem-based learning

In a presentation at the EnVision Summit 2023 in Puerto Rico, Sumayya Ahmad, MD, pointed out that for patients with lower Schirmer’s scores and corneal staining, PRK may be a good choice. If the dry eye can be treated preoperatively and the eye has no staining, surgeons can consider LASIK.

Surgeon notes there is no good solution for ending use of topical medications

Those attending the Asia-Pacific Academy of Ophthalmology congress In Kuala Lumpur can celebrate the reconvening of the congress after a 2-year hiatus by joining in the “We Are Back” Fundraising Run.

In addition to observation, laser-assisted vitreolysis and pars plana vitrectomy (PPV) are options, all of which deserve careful consideration.

Having the best tools available is of the utmost importance in the operating room (OR).

At the EnVision Summit Ophthalmology in Puerto Rico, Grace Sun, MD, made a presentation titled "Surgical Curriculum for Ophthalmology Residents" to train them to be competent in a broad range of basic and advanced surgical skills.

At the EnVision Summit Ophthalmology 2023 in Puerto Rico, Eva Kim, MD, made a presentation titled "ICL and Clear Lens Exchange: Choosing the Right Approach."

Corneal neurotization is an efficacious procedure to restore sensation to a neurotrophic cornea, involving the surgical transfer of sensory nerve fibers to the cornea.

During the EnVision Summit Ophthalmology in Puerto Rico, Victor Villegas, MD, made a presentation titled "From a Retina Perspective: Comanagement of AMD, DME and CME in the Setting of Cataract Surgery," focusing on how to comanage patients that have macular degeneration, diabetic maculopathy and cystoid macular edema.

David Huang, MD, PhD, is recognized as a co-creator of a widely used medical imaging technology.

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

According to the company, the app features new content, including podcasts, discussion forums and downloadable content for eyecare professionals.

During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.